Intranasal Drug Delivery for Neurodegenerative Diseases

Intranasal Drug Delivery for Neurodegenerative Diseases

Overview

Intranasal Drug Delivery for Neurodegenerative Diseases describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.

Intranasal drug delivery represents a promising non-invasive approach for targeting therapeutic agents to the central nervous system (CNS), bypassing the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) through the nasal cavity's unique anatomical pathways. This mechanism is particularly relevant for neurodegenerative diseases where effective CNS drug delivery remains a significant therapeutic challenge[@illum2004].

Anatomical Pathways

Olfactory Pathway

The olfactory pathway provides a direct route from the nasal cavity to the brain through the olfactory nerve. Drugs absorbed through the olfactory epithelium can travel along the olfactory nerve fibers to reach the olfactory bulb and subsequently other brain regions[@dhuria2010].

• Olfactory epithelium: Specialized sensory epithelium in the superior nasal cavity
• Olfactory bulb: First relay station in the brain for olfactory information
• Direct transport: Trigeminal nerve branches also provide access to brainstem and other regions

Trigeminal Pathway

...

Intranasal Drug Delivery for Neurodegenerative Diseases

Overview

Intranasal Drug Delivery for Neurodegenerative Diseases describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.

Intranasal drug delivery represents a promising non-invasive approach for targeting therapeutic agents to the central nervous system (CNS), bypassing the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) through the nasal cavity's unique anatomical pathways. This mechanism is particularly relevant for neurodegenerative diseases where effective CNS drug delivery remains a significant therapeutic challenge[@illum2004].

Anatomical Pathways

Olfactory Pathway

The olfactory pathway provides a direct route from the nasal cavity to the brain through the olfactory nerve. Drugs absorbed through the olfactory epithelium can travel along the olfactory nerve fibers to reach the olfactory bulb and subsequently other brain regions[@dhuria2010].

• Olfactory epithelium: Specialized sensory epithelium in the superior nasal cavity
• Olfactory bulb: First relay station in the brain for olfactory information
• Direct transport: Trigeminal nerve branches also provide access to brainstem and other regions

Trigeminal Pathway

The trigeminal nerve (CN V) provides additional neural pathways from the nasal cavity to the brain. The ophthalmic and maxillary divisions of the trigeminal nerve innervate the nasal mucosa and provide routes for drug transport to the brainstem and cerebrospinal fluid (CSF)[@kumar2020].

Advantages Over Systemic Delivery

| Advantage | Description |
|-----------|-------------|
| Bypasses BBB | Direct nose-to-brain transport avoids blood-brain barrier |
| Non-invasive | Avoids risks associated with intracranial delivery |
| Rapid onset | Direct neural pathways enable faster drug delivery to CNS |
| Reduced systemic exposure | Lower peripheral side effects compared to oral/IV delivery |
| Self-administration | Patient-friendly delivery method for chronic conditions |

Nanoparticles and Formulations

Lipid-Based Nanoparticles

Lipid-based carriers have shown particular promise for intranasal delivery:

• Solid lipid nanoparticles (SLNs): Biocompatible, controlled release
• Nanostructured lipid carriers (NLCs): Improved drug loading
• Liposomes: Versatile delivery vehicles for various therapeutics[@pardeshi2012]

Polymeric Nanoparticles

Polymeric nanoparticles offer customizable release profiles:

• Chitosan-based formulations enhance mucoadhesion
• PLGA nanoparticles provide sustained release
• Dendrimers enable targeted delivery

Surface Modifications

Surface modifications improve targeting and delivery efficiency:

• Mucoadhesive polymers: Extend residence time in nasal cavity
• Peptide conjugates: Target olfactory receptors
• PEGylation: Improve biocompatibility and reduce clearance

Applications for Neurodegenerative Diseases

Alzheimer's Disease

Intranasal delivery offers promise for [Alzheimer's disease](/diseases/alzheimers-disease) treatment:

• [Amyloid-beta](/proteins/amyloid-beta) targeting: Nasal vaccines and antibody delivery
• [Tau protein](/proteins/tau) modulation: Anti-tau nanoparticle formulations
• Neuroprotective agents: Coenzyme Q10, curcumin nanocarriers
• Growth factors: NGF and BDNF delivery for neuronal survival

Parkinson's Disease

For [Parkinson's disease](/diseases/parkinsons-disease-disease):

• Dopamine replacement: Nasal dopamine formulations
• Neuroprotective compounds: [GLP-1 receptor](/entities/glp1-receptor) agonists
• Gene therapy: Viral vector delivery via nasal route
• [Alpha-synuclein](/proteins/alpha-synuclein) targeting: Antibody and small molecule delivery

Amyotrophic Lateral Sclerosis

[ALS](/diseases/amyotrophic-lateral-sclerosis) applications include:

• Riluzole delivery: Enhanced CNS penetration
• SOD1 targeting: Gene silencing approaches
• Neurotrophic factors: BDNF and CNTF delivery
• Mitochondrial protectors: CoQ10 and idebenone formulations

Frontotemporal Dementia

[Frontotemporal dementia](/diseases/frontotemporal-dementia) research includes:

• Tau-targeting therapies: Antibody and small molecule delivery
• Neuroinflammation modulation: Anti-inflammatory nanoparticle approaches
• Microglial modulation: Targeted anti-inflammatory delivery

Huntington's Disease

[Huntington disease](/diseases/huntington-disease) applications:

• [Huntingtin](/proteins/huntingtin) gene silencing: siRNA and antisense oligonucleotide delivery
• Neuroprotective strategies: Antioxidant and anti-inflammatory formulations
• BDNF delivery: Promoting neuronal survival

Clinical Trials

Several clinical trials have investigated intranasal delivery for neurodegenerative diseases:

Intranasal insulin: Phase II trials for AD showed improved cognitive function with intranasal insulin administration[@craft2012]

Nasal CoQ10: Trials investigating mitochondrial support in PD

Nasal vaccines: Immunotherapy approaches for AD

Growth factor delivery: NGF and BDNF nasal formulations in early-phase trials

Challenges

Mucociliary Clearance

The nasal mucosa's natural clearance mechanisms present challenges:

• Ciliary beat frequency removes particles within 15-30 minutes
• Mucus production can trap and eliminate drug particles
• Solutions: mucoadhesive formulations, enzyme inhibitors

Dosage and Bioavailability

• Variable absorption across nasal cavity regions
• Limited dose volume (25-200 μL per nostril)
• Variable patient technique affecting delivery
• Solutions: precision delivery devices, reproducible formulations

Nasal Pathologies

• Rhinitis, sinusitis, and nasal polyps affect delivery
• Epithelial damage can increase or decrease absorption
• Patient selection important for optimal outcomes

Comparison to Other BBB Bypass Approaches

Focused Ultrasound

• Mechanism: Ultrasound opens BBB temporarily
• Invasiveness: Non-invasive but requires equipment
• Precision: Targeted opening of specific brain regions
• Integration: Can be combined with intranasal delivery

Convection-Enhanced Delivery

• Mechanism: Direct infusion under pressure
• Invasiveness: Requires intracranial catheters
• Coverage: Large brain volume coverage possible
• Advantage: No systemic exposure

Intranasal Delivery

• Mechanism: Neural pathways direct to brain
• Invasiveness: Non-invasive
• Coverage: Limited to olfactory/trigeminal regions
• Advantage: Simplest patient self-administration

Summary Comparison

| Method | Invasiveness | Patient-Friendly | Onset | CNS Coverage |
|--------|-------------|------------------|-------|---------------|
| Intranasal | Non-invasive | Yes | Fast | Olfactory/trigeminal |
| Focused Ultrasound | Non-invasive | No | Moderate | Targeted regions |
| Convection-Enhanced | Invasive | No | Fast | Large volumes |

Future Directions

Emerging Technologies

• 3D-printed nasal implants: Personalized delivery devices
• Exosome delivery: Cell-derived vesicles for targeted therapy
• Olfactory organoids: Advanced models for testing
• Gene editing delivery: CRISPR components via nasal route

Combination Approaches

• Intranasal delivery combined with focused ultrasound
• Nanoparticle cocktails targeting multiple pathways
• Personalized formulations based on patient genetics

See Also

• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease-disease)
• [Drug Delivery Mechanisms](/mechanisms/drug-delivery-mechanisms)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

Recent advances in intranasal drug delivery for neurodegeneration:

• Olfactory Targeting: New studies demonstrate enhanced delivery of therapeutic antibodies to the brain via olfactory pathway [(Illum, 2025)](https://doi.org/10.1016/j.jconrel.2025.01.025).
• Nanoparticle Formulations: Research on nanoparticle carriers continues to improve nose-to-brain drug delivery efficiency [(Kumar et al., 2024)](https://doi.org/10.1002/mco2.70213).
• Clinical Trials: Recent clinical trials have evaluated intranasal delivery of neuroprotective compounds in [Alzheimer's](/diseases/alzheimers-disease) and [Parkinson's](/diseases/parkinsons-disease) [(Ross et al., 2025)](https://doi.org/10.1186/s40035-025-00481-w).

References

[Illum, L., Is nose-to-brain delivery of drugs a sane undertaking? (CNS Drugs, 2004)](https://doi.org/10.2165/00023210-200418060-00004)

[Dhuria et al., Intranasal delivery to the central nervous system: mechanisms and experimental considerations (J Pharm Sci, 2010)](https://doi.org/10.1016/j.xphs.2010.04.005)

[Kumar et al., Advances in intranasal drug delivery for brain targeting (J Control Release, 2020)](https://doi.org/10.1016/j.jconrel.2020.10.031)

[Pardeshi et al., Solid lipid nanoparticles and nanostructured lipid carriers for nose-to-brain targeting (Recent Patents Drug Deliv Formul, 2012)](https://doi.org/10.2174/187231112800672869)

[Craft et al., Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment (Arch Neurol, 2012)](https://doi.org/10.1001/archneurol.2011.233)